Dysbiosis

CHICAGO, Sept. 11, 2024 /PRNewswire/ -- 32 Biosciences, pronounced "Three Squared Biosciences," proudly announces its emergence from stealth mode, with new microbiome diagnostic management tools and microbiome-based interventions. The company intends to revolutionize healthcare with its novel approach to gut microbiome medicine. Chronic diseases continue to pose a significant challenge despite years of progress in medical research and care. While medical advancements have extended lifespan, they have not necessarily improved health-span, partly due to a focus on treating illness rather than emphasizing preventive health. Additionally, scientists point to modern dietary habits and widespread antibiotic use as disrupting the gut microbiome—a crucial yet frequently neglected component of our health. The gut microbiome is increasingly recognized as a vital component of overall health, sometimes referred to as the sixth vital organ. Dysbiosis, or disruption of this intricate system, can lead to systemic inflammation, heightened infection risk, and a range of chronic diseases. As of now, there are no universally standardized measures for the functional health of the gut microbiome. 32 Biosciences is addressing this critical need with its gut microbiome platform technologies. One of its lead assets, GB-0001, is an advanced diagnostic management tool that aims to provide a standardized measure of functional gut microbiome health and have a direct impact on clinical decision-making. If approved, GB-0001 would help health care professionals monitor gut health while modifying medication and nutrition, ultimately restoring gut microbiome health. GB-0001 will also support the development of microbiome-based interventions for disease prevention and treatment such as CS-0003, a lead therapeutic asset intended to target virulent gene expression while promoting the growth of beneficial bacteria. Finally, 32 Biosciences plans to introduce science-based nutritional products to restore and maintain functional gut microbiome health. "At 32 Biosciences, we are pioneering a new approach to medicine by leveraging our advanced microbiome scientific research to create clinically validated physician management tools for diagnosing and addressing dysbiosis—an important factor in the development of many diseases," said Peter Farmakis, CEO. "Our intent is to better serve patients who currently have limited FDA-approved options and also to create significant financial value by addressing high unmet needs in large economic markets." The company's approach is built on research by scientific co-founders John Alverdy, MD, and Eugene Chang, MD, from The University of Chicago, and Joseph Pierre, PhD, from the University of Wisconsin-Madison. Their innovative microbiome research and development has been supported by $119 million in National Institutes of Health (NIH) grants. 32 Biosciences scientific founders partnered with The University of Chicago Duchossois Family Institute to produce GB-0001 and The University of Chicago Pritzker School of Molecular Engineering to produce CS-0003 technologies. About 32 Biosciences: 32 Biosciences is a healthcare company dedicated to advancing gut microbiome medicine. The company is committed to developing microbiome diagnostic management tools and microbiome-based interventions to enhance health-span by addressing the pivotal role of the gut microbiome in overall well-being. Established in 2023, 32 Biosciences was formalized as the parent company in April 2024 to wholly owned subsidiaries, Covira, established in 2018, and Gateway Biome, established in 2022. For more information, visit . Follow us on LinkedIn @32Biosciences. Media Contact: Julie Ferguson Healthcare Communications Consultant JFPR Media, LLC Email: [email protected] Phone: (312) 385-0098 SOURCE 32 Biosciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

THURSDAY, July 18, 2024 -- For solid organ transplant recipients, gut dysbiosis is associated with all-cause and cause-specific mortality, according to a study published online July 2 in Gut . J. Casper Swarte, from the University Medical Centre in Groningen, Netherlands, and colleagues analyzed 1,337 metagenomes derived from fecal samples of 766 kidney, 334 liver, 170 lung, and 67 heart transplant recipients from the TransplantLines Biobank and Cohort. An additional 8,208 metagenomes from the general population of the same geographical area were included to analyze gut dysbiosis. The association between multiple indicators of gut dysbiosis, including individual species abundances, and all-cause and cause-specific mortality was examined using multivariable Cox regression and a machine learning algorithm. The researchers identified two patterns representing microbiome community variation that were associated with all-cause and cause-specific mortality. There was an association between the gut microbiome distance between each transplantation recipient to the average of the general population with all-cause mortality and death from infection, malignancy, and cardiovascular disease. Twenty-three bacterial species that were associated with all-cause mortality were identified; a balance consisting of 19 of 23 species that were associated with all-cause mortality was identified by applying a machine learning algorithm. "Our results support emerging evidence showing that gut dysbiosis is associated with long-term survival, indicating that gut-microbiome targeting therapies might improve patient outcomes although causal links should be identified first," the authors write. The TransplantLines Biobank and Cohort study received funding from Astellas BV and Chiesi Pharmaceuticals BV.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced that it has entered into a definitive agreement with a consortia comprising Aarhus University, Skive Hospital and Statens Serum Institut of Denmark, and obtained the exclusive worldwide license to inventions resulting from an investigator-initiated Phase 2 trial of Osel’s investigational LBP, LACTIN-V, in women undergoing in-vitro fertilization (IVF). Financial terms were not disclosed. Osel is developing LACTIN-V, a proprietary formulation of Lactobacillus crispatus being studied in IVF, in addition to bacterial vaginosis (BV) and pre-term birth. Last year, Osel and colleagues published data in The New England Journal of Medicine demonstrating that LACTIN-V significantly reduced the recurrence of BV versus placebo in a Phase 2b trial. “Dysbiosis, or disruption of the vaginal microbiome, can lead to many problems in women’s health including BV and decreasing the success rate of IVF,” said Peter P. Lee, MD, Founder and Executive Chairman of Osel. “LACTIN-V, which contains the protective vaginal bacterial strain L. crispatus CTV-05, could help promote a healthier vaginal microbiome for IVF.” Under the agreement, the ongoing Phase 2 IVF trial is being conducted at four fertility clinics in Denmark and led by Professor Peter Humaidan, MD, Aarhus University and Skive Regional Hospital. The primary endpoint of the trial is clinical pregnancy at seven weeks post-embryo transfer in women with documented abnormal vaginal microbiota, which lowers the probability of successful IVF. “The vaginal microbiome and its importance for fertility is an intriguing new field of research. In the near future we hope to be able to define the most optimal vaginal microbiome – and importantly, to be able to modify the abnormal to normal,” said Professor Humaidan. “The ultimate goal of our research is to improve success rates of not only IVF, but also spontaneous pregnancy.” “LACTIN-V holds promise as the first treatment to increase the possibility of pregnancy from IVF, especially in women with vaginal dysbiosis,” said Thomas Parks, PhD, Director of Product Development at Osel. “While the trial’s progress was impacted by COVID-19, we expect to complete enrollment by the end of 2021/early 2022.” About Osel, Inc. Osel, Inc., a privately held biopharmaceutical company based in Mountain View, California, is focused on the development and commercialization of a portfolio of live biotherapeutic products (LBPs) to prevent or treat medical conditions resulting from disruption of the human microbiome (dysbiosis). The company is a pioneer in the field of LBPs, with a primary focus in women’s health. While many current microbiome treatments involve microbial transplants that are collected and processed from donor pools, Osel focuses on rigorously selected single strain products that are highly reproducible, scalable, and safe. Visit oselinc.com to learn more.